Marijuana Rescheduling Appeal Process 'Remains Pending' Despite Trump's Executive Order, DEA Says In New Filing - Marijuana Moment
Marijuana Rescheduling Appeal Process 'Remains Pending' Despite Trump's Executive Order, DEA Says In New Filing - Marijuana Moment — rescheduling update affecting Pharmaceutical Manufacturing (FDA/DEA).
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 15, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)) should confirm how it applies to their specific situation before acting. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed. Regulated niches like Pharmaceutical Manufacturing (FDA/DEA) move faster than most operators can track by hand, which is why Aforeworn watches the official sources for you and flags every material change the moment it appears.
What changed
Marijuana Rescheduling Appeal Process 'Remains Pending' Despite Trump's Executive Order, DEA Says In New Filing - Marijuana Moment
Who it affects
Pharmaceutical Manufacturing (FDA/DEA) (branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B))
What you must do
Read the update and assess whether your current setup needs to change.
Deadline
No fixed deadline was published, but changes like this are often enforced quickly — act promptly.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Statistical Considerations for the Design of Rare Disease Clinical Investigations; Establishment of a Public Docket; Request for Information and Comments
- Lilly Plans Four New Pharmaceutical Manufacturing Sites in the U.S. - Contract Pharma
- Pharmalittle: We're reading about FDA reforming clinical trials, a Pfizer setback, and much more news - statnews.com
- US FDA proposes rule to simplify registration for some drug manufacturers - reuters.com
- AG Sunday, Partners Announce Charges Against 12 People in Multi-Million-Dollar Drug Trafficking Ring Involving High-Potency THC Products Sold in Stores